Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 65Active not recruiting 39Completed 15Terminated 10Not yet recruiting 4Withdrawn 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Glioblastoma 1Breast Neoplasms 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 13Specimen Handling 12Cyclophosphamide 10fludarabine 9Radiotherapy 9Biopsy 8atezolizumab 7Nivolumab 7Radiation 6Prednisone 4Gemcitabine 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4ALT-803 4lenvatinib 3fludarabine phosphate 3avelumab 3aldesleukin 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3Paclitaxel 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × abemaciclib × 1 year × Clear all
NCT06585969 2026-02-12

DISCORDANT

Danish Breast Cancer Cooperative Group

Phase 3 Withdrawn
Breast

Breast Neoplasms

NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡